lutetium has been researched along with evans blue in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bandara, N; Chen, X; Jacobson, O; Mpoy, C; Rogers, BE | 1 |
| Chen, X; Jacobson, O; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Szajek, LP; Tian, R; Wang, Z | 1 |
| Akbarian, R; Fattahi, K; Ghodsirad, MA; Javanmard, B; Kaghazchi, F; Pirayesh, E; Tavakoli, M | 1 |
3 other study(ies) available for lutetium and evans blue
| Article | Year |
|---|---|
Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Evans Blue; Heterografts; Humans; Lutetium; Mice; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Theranostic Nanomedicine; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2018 |
Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.
Topics: Animals; Dipeptides; Evans Blue; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2018 |
Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.
Topics: Aged; Aged, 80 and over; Dipeptides; Evans Blue; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2020 |